Effectiveness of Mirena® LNG-IUS in treating women with endometrial hyperplasia and climacteric syndrome

Abstract

Introduction and Aim: Endometrial hyperplasia (EH) is a common cause of malignant tumors and a major health risk for perimenopausal women. In this study, systemic immunological markers in women with climacteric syndrome (CS) and EH will be examined in relation to the EH treatment option Mirena® levonorgestrel-releasing intrauterine device (LNG-IUS).   Materials and Methods: Examining 350 premenopausal women, 84 (23.4%) were diagnosed with EH. The type of EH was identified in 84 patients using a histological study and a diagnostic curettage of the uterine cavity. In view of more severe and considerable systemic immunity abnormalities in women with CS and EH, the indirect effect of levonorgestrel's intrauterine microdose excretion on systemic immunity was examined.   Results: Mirena® LNG-IUS has an indirect immune-corrective effect on systemic and humoral immunity in women with EH who have a pathological climatic course. It does this by stabilizing the neutrophil pool, activating the receptor function, and stabilizing the absorption and metabolic activity of neutrophilic phagocytes in the humoral system.   Conclusion: Due to the pathological progression of menopause and the appearance of EH, alterations in women's reproductive system during this period led to a significant decrease in the signs of CS after the first month of using Mirena® LNG-IUS.